PMC:7796052 / 9356-10241 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"267","span":{"begin":0,"end":10},"obj":"Gene"},{"id":"268","span":{"begin":32,"end":43},"obj":"Gene"},{"id":"269","span":{"begin":194,"end":198},"obj":"Gene"},{"id":"270","span":{"begin":203,"end":207},"obj":"Gene"},{"id":"271","span":{"begin":221,"end":225},"obj":"Gene"},{"id":"272","span":{"begin":226,"end":230},"obj":"Gene"},{"id":"273","span":{"begin":532,"end":536},"obj":"Gene"},{"id":"274","span":{"begin":474,"end":476},"obj":"Gene"},{"id":"275","span":{"begin":147,"end":149},"obj":"Gene"},{"id":"276","span":{"begin":665,"end":670},"obj":"Species"},{"id":"277","span":{"begin":386,"end":396},"obj":"Chemical"},{"id":"278","span":{"begin":741,"end":751},"obj":"Chemical"},{"id":"279","span":{"begin":90,"end":101},"obj":"Disease"},{"id":"280","span":{"begin":267,"end":278},"obj":"Disease"},{"id":"281","span":{"begin":686,"end":708},"obj":"Disease"}],"attributes":[{"id":"A267","pred":"tao:has_database_id","subj":"267","obj":"Gene:3827"},{"id":"A268","pred":"tao:has_database_id","subj":"268","obj":"Gene:624"},{"id":"A269","pred":"tao:has_database_id","subj":"269","obj":"Gene:3569"},{"id":"A270","pred":"tao:has_database_id","subj":"270","obj":"Gene:3576"},{"id":"A271","pred":"tao:has_database_id","subj":"271","obj":"Gene:5594"},{"id":"A272","pred":"tao:has_database_id","subj":"272","obj":"Gene:3726"},{"id":"A273","pred":"tao:has_database_id","subj":"273","obj":"Gene:3569"},{"id":"A274","pred":"tao:has_database_id","subj":"274","obj":"Gene:3827"},{"id":"A275","pred":"tao:has_database_id","subj":"275","obj":"Gene:3827"},{"id":"A276","pred":"tao:has_database_id","subj":"276","obj":"Tax:9606"},{"id":"A277","pred":"tao:has_database_id","subj":"277","obj":"MESH:D020849"},{"id":"A278","pred":"tao:has_database_id","subj":"278","obj":"MESH:D020849"},{"id":"A279","pred":"tao:has_database_id","subj":"279","obj":"MESH:D007022"},{"id":"A280","pred":"tao:has_database_id","subj":"280","obj":"MESH:D007022"},{"id":"A281","pred":"tao:has_database_id","subj":"281","obj":"MESH:D002318"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Bradykinin signaling though the B2 receptor induces a proinflammatory action as well as a hypotensive effect [33]. The proinflammatory activity of BK involves the stimulation of cytokines, like IL-6 and IL-8, through the MAPK/AP-1 signaling axis [17,34], whereas the hypotensive effects are due to vasodilation and increased vascular permeability. Due to the partial agonist profile of raloxifene, it is expected that the compound antagonizes the proinflammatory effects of BK, modulating the levels of diverse cytokines, including IL-6. To support this hypothesis, in clinical trials aimed at understanding the effect of hormone replacement therapy for menopausal women on the risk of cardiovascular disease, in contrast to other compounds raloxifene did not exhibit a proinflammatory profile [35,36] that could, in part, be explained by its antagonistic effect on the BK B2 receptor."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T14","span":{"begin":686,"end":708},"obj":"Phenotype"}],"attributes":[{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0001626"}],"text":"Bradykinin signaling though the B2 receptor induces a proinflammatory action as well as a hypotensive effect [33]. The proinflammatory activity of BK involves the stimulation of cytokines, like IL-6 and IL-8, through the MAPK/AP-1 signaling axis [17,34], whereas the hypotensive effects are due to vasodilation and increased vascular permeability. Due to the partial agonist profile of raloxifene, it is expected that the compound antagonizes the proinflammatory effects of BK, modulating the levels of diverse cytokines, including IL-6. To support this hypothesis, in clinical trials aimed at understanding the effect of hormone replacement therapy for menopausal women on the risk of cardiovascular disease, in contrast to other compounds raloxifene did not exhibit a proinflammatory profile [35,36] that could, in part, be explained by its antagonistic effect on the BK B2 receptor."}

{"project":"LitCovid-sentences","denotations":[{"id":"T62","span":{"begin":0,"end":114},"obj":"Sentence"},{"id":"T63","span":{"begin":115,"end":347},"obj":"Sentence"},{"id":"T64","span":{"begin":348,"end":537},"obj":"Sentence"},{"id":"T65","span":{"begin":538,"end":885},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Bradykinin signaling though the B2 receptor induces a proinflammatory action as well as a hypotensive effect [33]. The proinflammatory activity of BK involves the stimulation of cytokines, like IL-6 and IL-8, through the MAPK/AP-1 signaling axis [17,34], whereas the hypotensive effects are due to vasodilation and increased vascular permeability. Due to the partial agonist profile of raloxifene, it is expected that the compound antagonizes the proinflammatory effects of BK, modulating the levels of diverse cytokines, including IL-6. To support this hypothesis, in clinical trials aimed at understanding the effect of hormone replacement therapy for menopausal women on the risk of cardiovascular disease, in contrast to other compounds raloxifene did not exhibit a proinflammatory profile [35,36] that could, in part, be explained by its antagonistic effect on the BK B2 receptor."}